You are here

Article info

Article menu
Download PDFPDF
Correspondence
Rational use of tocilizumab in COVID-19

Authors

  • Siddharth Jain Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India PubMed articlesGoogle scholar articles
  • Shefali Khanna Sharma Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Shefali Khanna Sharma, Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India; sharmashefali{at}hotmail.com
View Full Text

Citation

Jain S, Sharma SK
Rational use of tocilizumab in COVID-19
Annals of the Rheumatic Diseases 2022;81:e213.

Publication history

  • Received July 4, 2020
  • Revised July 11, 2020
  • Accepted July 15, 2020
  • First published July 31, 2020.
Online issue publication 
August 01, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage